BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10404342)

  • 1. Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters.
    Shah PM; Schwärzel R
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():71-5. PubMed ID: 10404342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae.
    Shah PM
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():61-5. PubMed ID: 10404340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
    Bauernfeind A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 1999 Jan; 43(1):79-86. PubMed ID: 10381104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.
    Thomson KS; Chartrand SA; Sanders CC; Block SL
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():15-9. PubMed ID: 10404332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae.
    Lister PD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):43-9. PubMed ID: 12376030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
    Reinert RR; Lütticken R; Lemperle M; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
    J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of extremely high penicillin and cefotaxime resistance and high-level levofloxacin resistance in clinical isolates of Streptococcus pneumoniae in Hungary.
    Glatz K; Szabó D; Szabó G; Boriszova D; Rozgonyi F
    J Antimicrob Chemother; 2001 Nov; 48(5):731-4. PubMed ID: 11679565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
    Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
    Fukuda Y; Takahata M; Mitsuyama J
    J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.